Onconetix (ONCO) Invested Capital (2022 - 2026)

Onconetix (ONCO) has reported Invested Capital for 5 consecutive years, with $14.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital fell 27.36% year-over-year to $14.3 million in Q2 2026; TTM through Jun 2026 was $14.3 million, a 27.36% decrease from a year earlier, with the FY2025 full-year figure at $27.7 million, up 21.33% from the prior year.
• Invested Capital was $14.3 million for Q2 2026 at Onconetix, up from $12.9 million in the prior quarter.
• Over five years, Invested Capital peaked at $51.0 million in Q3 2024 and troughed at -$18.5 million in Q2 2024.
• A 5-year average of $17.9 million and a median of $19.7 million in 2023 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital slumped 183.58% in 2024 and surged 1875.73% in 2025, its largest moves.
• Over 5 years, Invested Capital stood at $23.0 million in 2022, then tumbled by 51.5% to $11.1 million in 2023, then soared by 105.27% to $22.9 million in 2024, then increased by 21.33% to $27.7 million in 2025, then tumbled by 48.59% to $14.3 million in 2026.
• The last three Invested Capital figures came in at $14.3 million (Q2 2026), $12.9 million (Q1 2026), and $27.7 million (Q4 2025), per Business Quant data.